Know What's Happening in Technology

Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity

Researchers have engineered an M13 filamentous phage vector, termed SCP, that simultaneously displays dendritic‑cell targeting peptides and SpyCatcher proteins for antigen conjugation. In vitro, SCP activates dendritic cells, increasing co‑stimulatory markers and inflammatory gene signatures, which translates into enhanced cytotoxic T‑cell activity. In multiple murine tumour models, subcutaneous or intratumoral administration of SCP triggers local inflammation, immunogenic cell death, reduces neovascularisation, and drives robust tumour‑specific T‑cell responses without the need for predefined neoantigens. The platform is presented as scalable, low‑cost, and adaptable, offering a potentially accessible alternative to current personalized cancer vaccines.